DMXAA Causes Tumor Site-Specific Vascular Disruption in Murine Non-Small Cell Lung Cancer, and like the Endogenous Non-Canonical Cyclic Dinucleotide STING Agonist, 2′3′-cGAMP, Induces M2 Macrophage Repolarization

Neutrophil Influx and Chemokine Production during the Early Phases of the Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404)

(2015) Liang-Chuan S. Wang et al.   NEOPLASIA

Acute Vascular Disruption by 5,6-Dimethylxanthenone-4-Acetic Acid in an Orthotopic Model of Human Head and Neck Cancer

(2014) Mukund Seshadri et al.   Translational Oncology

Modifying tumor-associated macrophages

(2014) Zvi G Fridlender et al.   OncoImmunology

Anticancer Flavonoids Are Mouse-Selective STING Agonists

(2013) Sujeong Kim et al.   ACS Chemical Biology

Using macrophage activation to augment immunotherapy of established tumours

(2013) Z G Fridlender et al.   BRITISH JOURNAL OF CANCER

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

(2013) S M Tijono et al.   BRITISH JOURNAL OF CANCER

Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid

(2013) J. Conlon et al.   JOURNAL OF IMMUNOLOGY

STING-dependent cytosolic DNA sensing pathways

(2013) Glen N. Barber   TRENDS IN IMMUNOLOGY

Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes

(2012) M. Singh et al.   CANCER RESEARCH

5,6-Dimethylxanthenone-4-acetic Acid (DMXAA) Activates Stimulator of Interferon Gene (STING)-dependent Innate Immune Pathways and Is Regulated by Mitochondrial Membrane Potential

(2012) Daniel Prantner et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Macrophage plasticity and polarization: in vivo veritas

(2012) Antonio Sica et al.   JOURNAL OF CLINICAL INVESTIGATION

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

(2012) Zhao Chen et al.   NATURE

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

(2012) Martin Peifer et al.   NATURE GENETICS

Quantitative Ex-Vivo Micro-Computed Tomographic Imaging of Blood Vessels and Necrotic Regions within Tumors

(2012) Charlene M. Downey et al.   PLoS One

Differentiation and gene expression profile of tumor-associated macrophages

(2012) Astrid Schmieder et al.   SEMINARS IN CANCER BIOLOGY

HMGB1 Is a Therapeutic Target for Sterile Inflammation and Infection

(2011) Ulf Andersson et al.   Annual Review of Immunology

Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation

(2011) Jing Sun et al.   BIOCHEMICAL PHARMACOLOGY

HRG Inhibits Tumor Growth and Metastasis by Inducing Macrophage Polarization and Vessel Normalization through Downregulation of PlGF

(2011) Charlotte Rolny et al.   CANCER CELL

Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment

(2011) P. Allavena et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Modularity in the skull and cranial vasculature of laboratory mice: implications for the evolution of complex phenotypes

(2011) Heather A. Jamniczky et al.   EVOLUTION & DEVELOPMENT

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

(2011) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY

How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers

(2011) Katerina Politi et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Development of Vascular Disrupting Agents: What Lessons Can We Learn From ASA404?

(2011) Patricia M. LoRusso et al.   JOURNAL OF CLINICAL ONCOLOGY

STING is a direct innate immune sensor of cyclic di-GMP

(2011) Dara L. Burdette et al.   NATURE

TGF-β-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth

(2011) T J Standiford et al.   ONCOGENE

Disrupting established tumor blood vessels

(2010) Mark J. McKeage et al.   CANCER

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC

(2010) R. Pili et al.   CLINICAL CANCER RESEARCH

The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities

(2010) Michelle Head et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Temporal aspects of the action of ASA404 (vadimezan; DMXAA)

(2010) Bruce C Baguley et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression

(2009) D. L. Gibbons et al.   GENES & DEVELOPMENT

A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP

(2009) Sarah M. McWhirter et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Lysyl Oxidase Inhibitor, β-Aminopropionitrile, Diminishes the Metastatic Colonization Potential of Circulating Breast Cancer Cells

(2009) Alla Bondareva et al.   PLoS One

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

(2008) M J McKeage et al.   BRITISH JOURNAL OF CANCER

“Re-educating” tumor-associated macrophages by targeting NF-κB

(2008) Thorsten Hagemann et al.   JOURNAL OF EXPERIMENTAL MEDICINE